Résumé
Aim To investigate the inhibitory effect of small molecule inhibitors of ornithine decarboxylase inhibitor 1 (AZIN-1) on non-small cell lung cancer and its mechanism. Methods Cell proliferation was detected by Cell Counting Kit-8 (CCK-8). Apoptosis was analyzed by flow cytometry (PI/Annexin V-FITC double staining). The expression of ornithine decarboxylase (ODC), ornithine decarboxylase anti-enzyme-1 (AZ-1) and AZIN-1 was detected by Western blot. Cell cycle was analyzed by flow cytometry (PI single staining). The total polyamine content in cellswas measured by high performance liquid chromatography (HPLC). Results Small molecule inhibitor of AZIN-1 could significantly inhibit the proliferation of A549 cells, cause G0/G, cycle arrest, induce apoptosis of A549 cells, inhibit the expression of AZIN-1 and ODC, interfere with intracellular polyamine metabolism, and reduce total polyamine content in cells. Conclusions Small molecule inhibitor of AZIN-1 has significant growth inhibitory effect on A549 cells, and its mechanism may be related to the induction of apoptosis and interference with polyamine metabolism.
Résumé
Objective In a RCT study, the safety and efficacy of sabot (a slow-release salbuteral) and volmax (controlled-release salbuterol) were compared in bronchial asthma. Methods 40 patients with moderate to severe asthma were randomly divided into two groups and treated by sabot or volmax for 2 weeks. The FEV1%, peak expiratory flow (PEF), symptom score and use of rescue ventolin were measured to evaluate the effect of treatment. Results After treatment FEV1%, PEF and symptom score improved and the need for inhaling short-acting beta 2-agonis in both groups reduced significantly. There was no difference of these improvement between two groups. Conclusion The safety and efficacy of sabot for treatment of asthma was similar to volmax.
Résumé
Objective In a RCT study, the safety and efficacy of sabot (a slow-release salbuteral) and volmax (controlled-release salbuterol) were compared in bronchial asthma. Methods 40 patients with moderate to severe asthma were randomly divided into two groups and treated by sabot or volmax for 2 weeks. The FEV1%, peak expiratory flow (PEF), symptom score and use of rescue ventolin were measured to evaluate the effect of treatment. Results After treatment FEV1%, PEF and symptom score improved and the need for inhaling short-acting beta 2-agonis in both groups reduced significantly. There was no difference of these improvement between two groups. Conclusion The safety and efficacy of sabot for treatment of asthma was similar to volmax.